Singapore markets closed
Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,433.76 +52.41 (+0.63%) Bitcoin USD
60,947.41 -2,030.72 (-3.22%) CMC Crypto 200
1,261.13 -96.88 (-7.13%)
Cipla Limited (CIPLA.NS)
NSE - NSE Real-time price. Currency in INR
Add to watchlist
At close: 03:30PM IST
| Previous close | 1,358.80 |
| Open | 1,371.35 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 1,317.25 - 1,396.90 |
| 52-week range | 896.85 - 1,519.00 |
| Volume | |
| Avg. volume | 1,549,049 |
| Market cap | 1.082T |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 29.17 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 8.50 (0.63%) |
| Ex-dividend date | 21 Jul 2023 |
| 1y target est | N/A |
- PR Newswire
Cipla announces joint venture in the United States with Kemwell Biopharma and Manipal Education & Medical Group for global development and commercialisation of innovative Cell therapy products
Cipla (EU) Limited, UK a wholly owned subsidiary of Cipla Limited (BSE:500087; NSE: Cipla EQ], hereinafter referred to as Cipla has announced a strategic collaboration with Kemwell Biopharma Private Limited (through its subsidiary Kemwell Biopharma UK Limited) and Manipal Education & Medical Group (through its subsidiary MNI Ventures, Mauritius) to incorporate a joint venture in the United States. The primary goal of this joint venture is to develop and commercialise novel Cell therapy products
© 2024 Yahoo. All rights reserved.